UPDATE: The deal priced at $20 and traded to $30. There have been some other dissenting voices like this one from Tim Mullany at MarketWatch. He's a little harsh on the company and is a little unfair at focusing in on medical issues versus general health and fitness. I know many passionate Fitbit users who are very healthy, active and young. They skew more to the "performance" side of things. We clearly agree on the risks facing Fitbit . . .